Viridian Therapeutics (VRDN) Price & Analysis

Compare

1,441 Followers

VRDN Stock Chart & Stats

$32.46

-$0.90(-4.30%)

At close: Jan 08 4:00 PM EST

$32.46

-$0.90(-4.30%)

Day’s Range― - ―

52-Week Range$9.90 - $32.54

Previous CloseN/A

Volume201.32K

Average Volume (3M)814.59K

Market Cap

$2.10B

Enterprise Value$789.25M

Total Cash (Recent Filing)$490.90M

Total Debt (Recent Filing)$23.82M

Price to Earnings (P/E)―

Beta1.63

Next Earnings

Mar 05, 2026

EPS Estimate

-0.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding93,093,030

10 Day Avg. Volume1,087,693

30 Day Avg. Volume814,586

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)1.94

Price to Sales (P/S)4309.19

P/FCF Ratio-5.59

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue11.15

Enterprise Value/Gross Profit11.15

Enterprise Value/Ebitda-2.64

Forecast

1Y Price Target

$40.39

Price Target Upside24.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityRecent financial transactions strengthen the balance sheet, ensuring the company is funded through profitability.

Product DevelopmentThe bigger value driver is the subcutaneously administered VRDN-003, with top-line Phase III data expected soon.

Regulatory MilestonesVRDN recently completed the submission of the veligrotug BLA, and potential FDA Priority review could lead to a regulatory decision by mid-2026.

Bears Say

Investment RisksRisks to an investment in Viridian are primarily clinical, regulatory, and commercial, with competition and differentiation challenges in the commercial setting.

Viridian Therapeutics News

Viridian Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $47 fair value estimate. The...

3d ago

VRDN

Viridian Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $47 price target Published first...

3d ago

VRDN

Viridian Therapeutics initiated with a Buy at Truist

Truist initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and $41 price target The firm, which...

12d ago

VRDN

Viridian Therapeutics price target raised to $45 from $41 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $45 from $41 and keeps an...

29d ago

VRDN

Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $40 from $30 and keeps a...

29d ago

VRDN

Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics

TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating on...

15d ago

VRDN

Viridian Therapeutics Advances Toward Profitability with Strategic Moves

Viridian Therapeutics, Inc. ( ($VRDN) ) has released its Q3 earnings. Here is a breakdown of the information...

29d ago

VRDN

Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability

Needham analyst Serge Belanger has maintained their bullish stance on VRDN stock, giving a Buy rating today. Serge...

1M ago

VRDN

Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)

Reports Q3 revenue $70.57M, consensus $11.72M. “The Viridian team continues to deliver strong results, highlighted by the successful...

1M ago

VRDN

Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing

Analyst Julian Harrison of BTIG reiterated a Buy rating on Viridian Therapeutics, retaining the price target of $61.00....

1M ago

VRDN

Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics and keeping the price target...

1M ago

VRDN

Viridian Therapeutics submits BLA to the FDA for veligrotug

Viridian Therapeutics (VRDN) announced the submission of its BLA to the FDA for veligrotug, the company’s investigational therapy...

1M ago

VRDN

Viridian Therapeutics’ Promising Phase 3 Trial for Thyroid Eye Disease

Viridian Therapeutics, Inc. (($VRDN)) announced an update on their ongoing clinical study. Viridian Therapeutics, Inc. is conducting a...

1M ago

VRDN

Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease

Viridian Therapeutics, Inc. (($VRDN)) announced an update on their ongoing clinical study. Viridian Therapeutics, Inc. is conducting a...

1M ago

VRDN

VRDN FAQ

What was Viridian Therapeutics’s price range in the past 12 months?

Viridian Therapeutics lowest stock price was $9.90 and its highest was $32.54 in the past 12 months.

What is Viridian Therapeutics’s market cap?

Viridian Therapeutics’s market cap is $2.10B.

When is Viridian Therapeutics’s upcoming earnings report date?

Viridian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 89 days.

How were Viridian Therapeutics’s earnings last quarter?

Viridian Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.679.

Is Viridian Therapeutics overvalued?

According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics pay dividends?

Viridian Therapeutics does not currently pay dividends.

What is Viridian Therapeutics’s EPS estimate?

Viridian Therapeutics’s EPS estimate is -0.97.

How many shares outstanding does Viridian Therapeutics have?

Viridian Therapeutics has 93,093,030 shares outstanding.

What happened to Viridian Therapeutics’s price movement after its last earnings report?

Viridian Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 8.293%.

Which hedge fund is a major shareholder of Viridian Therapeutics?

Currently, no hedge funds are holding shares in VRDN

Viridian Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.40%

Trailing 12-Months

Asset Growth

-0.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viridian Therapeutics

Viridian Therapeutics (VRDN) is a biopharmaceutical company focused on developing innovative therapies for patients with serious and rare diseases. The company operates in the biotechnology sector and specializes in the discovery and development of monoclonal antibodies that target specific disease mechanisms. Viridian's core products include biologic therapies aimed at treating conditions such as thyroid eye disease and other autoimmune disorders, leveraging its proprietary technology platforms to create novel treatment options.

Viridian Therapeutics (VRDN) Earnings & Revenues

Historic Earnings Reports

VRDN Stock 12 Month Forecast

Average Price Target

$40.39

▲(24.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","62":"$62","23.75":"$23.8","36.5":"$36.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.1205069,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,23.75,36.5,49.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,33.723076923076924,35.996153846153845,38.26923076923077,40.54230769230769,42.815384615384616,45.08846153846154,47.36153846153846,49.63461538461539,51.9076923076923,54.18076923076923,56.45384615384616,58.72692307692307,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,32.137692307692305,32.825384615384614,33.51307692307692,34.20076923076923,34.88846153846154,35.576153846153844,36.26384615384615,36.95153846153846,37.63923076923077,38.32692307692308,39.01461538461538,39.70230769230769,{"y":40.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,30.11696206923077,28.783924138461536,27.450886207692307,26.117848276923077,24.784810346153847,23.451772415384614,22.118734484615384,20.78569655384615,19.45265862307692,18.11962069230769,16.78658276153846,15.453544830769228,{"y":14.1205069,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >